SMAD6 Genotype Predicts Neurodevelopment in Non-syndromic Craniosynostosis.
De-novo or rare transmitted mutations in the SMAD6 gene affect non-syndromic midline synostosis (NSC) in 7% of patients. This study aimed to determine the neurocognitive sequelae of SMAD6 NSC. NSC patients >6 years of age, with SMAD6 mutations and non-SMAD6 NSC controls, were recruited. All patients completed a double-blinded neurodevelopmental battery (Wechsler Fundamentals, Wechsler Abbreviated Scale of Intelligence, Beery-Buktenica Developmental test), and parents/guardians completed behavioral surveys (Behavior Rating Inventory of Executive Function and Behavior Rating System for Children]. Twenty-eight patients participated: ten known SMAD6 (average age 10 years; 1 female; 8 metopic, 2 sagittal; 9 treated with CVR, 1 strip) and eighteen non-SMAD6 controls (age 9.5 years; 3 female; 12 metopic, 6 sagittal; 17 CVR, 1 strip). There were no differences between all 20 demographics. Individual correlations between scores and demographics revealed testing age, surgical age, parental education, and household income correlated with cognition. After controlling for these factors, SMAD6 patients performed worse on performance IQ(p=0.045), full IQ(p=0.035, and motor coordination(p=0.011), and worse on numerical operations(p=0.046), performance IQ(p=0.018), full IQ(p=0.010), and motor coordination(p=0.043) compared to age/race/gender/synostosis/operation matched controls. On behavioral surveys, SMAD6 scored worse on fourteen assessments including aggression, communication, and behavioral regulation. This prospective double-blinded study revealed that neuropsychiatric development of NSC may be under genetic control. SMAD6 mutations led to poorer performance on mathematics, performance-IQ, full-IQ, and motor coordination, even after controlling for exogenous factors, as well as behavior. Genetic testing may be critical for advocating early adjunctive neurodevelopmental therapy in patients with NSC.